MyoKardia Announces Exploratory Digital Health Substudy As Part Of PIONEER-HCM Trial Of MYK-461 In Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients

Trial to Assess Potential Effects of MYK-461 Treatment on Arterial Pulse Wave Morphology as Measured by Investigational Optical Biosensor Wristband

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced an exploratory digital health substudy that is under way as part of the Company's PIONEER-HCM trial of MYK-461 in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients.

The digital health exploratory objective of the trial assesses the potential effects of MYK-461 on the arterial pulse wave using an investigational photoplethysmography (PPG) biosensor. Data collected with the biosensor will be compared with traditional measures of disease. Abnormal arterial flow patterns have been previously observed in HCM patients using conventional tools such as echocardiography. This substudy will investigate whether a non-invasive investigational PPG wristband, similar to commercially available digital health wearables, could provide information to supplement standard measures and support development of a digital biomarker for treating oHCM patients.

Use of the investigational PPG wristband is part of a partnership between MyoKardia and Wavelet Health, a wearable technology platform for health research. The wristband shines beams of light onto the skin to measure patterns of blood flow in the wrist with each heartbeat. Data from the PPG signal will be analyzed with Wavelet's proprietary algorithms to characterize the blood flow patterns of the oHCM patients in the study.

"Wearable devices will likely play a transformative role in how we gather, analyze and interpret medical information," said Steven Steinhubl, M.D., director of digital medicine for Scripps Translational Science Institute. "Early investigational research in this field is an important first step in seeking validation of their considerable potential."

MyoKardia anticipates that the technology in this study, while investigational, could be applied in longitudinal studies to provide insight into patient physiology during daily activities as well as potential response to treatment.

If you liked this article you might like

MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback

The Right Side Is Still the Long Side

MyoKardia Shares Almost Double on Latest Clinical Data for Heart Disease Treatment